Medtronic (MDT) concentration risks

The company's disclosed concentration is on the supply and manufacturing side, with two distinct but related exposures. First, certain components, raw materials, and services needed to manufacture products are obtained from sole suppliers — a high-share exposure with a dependency character. Sole-source input relationships represent the most acute form of supply concentration: there is no disclosed qualified backup, so any disruption at a sole supplier — whether from capacity constraints, natural disaster, financial distress, or regulatory action — could halt production without a near-term alternative. Second, and compounding the first, several key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities — also a high-share exposure with a dependency character. The facility-level sterilization constraint adds a second layer of concentration: even if raw materials are available, a disruption at the specific sterilization site could prevent finished product from reaching customers, and the disclosure of constrained capacity and limited alternatives signals that this cannot be quickly resolved by shifting volume elsewhere. Together the two exposures create a layered supply risk: materials reliant on sole sources, processed through facilities with limited backup. There is no disclosed customer, geographic, or product concentration layered on top. On balance, manufacturing supply resilience — specifically sole-source component availability and sterilization facility continuity — are the primary variables investors should monitor in this concentration profile.

For the engine’s reasoning on MDT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.